ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1759

Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial

stéphanie Ferrero 1, Ruth Wittoek 2, Edem Allado 3, Coralie Cruzel 4, Véronique Breuil 1, Liana Euller Ziegler 5, Damien louille 6, Christian Roux7 and Joel Kremer 8, 1University of Nice, nice, France, 2Ghent University Hospital, Gent University, Gent, Belgium, 3Centre Hospitalier Universitaire de Nancy, Nancy, France, 4Université Cote d'Azur, nice, France, 5PUPH CHU NICE, nice, France, 6Université Cote d'Azur, Nancy, France, 7Université Cote d'Azur, Nice, 8Albany Medical College, Albany, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Hand disorders, methotrexate (MTX), Osteoarthritis, radiography and MRI

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: 4M046: Plenary II (1758–1763)

Session Type: Plenary Session II

Session Time: 11:00AM-12:30PM

Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the effect of MTX on pain and structural progression in symptomatic erosive HOA (EHOA).

Methods: This 1-year prospective, monocentric, randomized, double-blind, placebo-controlled study (NCT1968405) followed patients with symptomatic EHOA. Patients were randomized into two groups: 10 mg MTX per week or placebo. The primary endpoint was pain assessment at 3 months, and secondary endpoints were clinical features (pain on visual analog scale (VAS)), radiographic features (Verbruggen anatomical radiographic score and Gent University Score System), and magnetic resonance imaging (MRI) at 12 months.

Results: Sixty-four EHOA patients were randomized to either the placebo or MTX group. At 3 months, there was no significant difference in the mean decrease in VAS pain score (mm) (MTX: 17.5 (28.4) vs placebo: 8.4 (25.2); p=0.2). Erosive joints progressed significantly more to a remodeling phase in the MTX group than in the placebo group (27% vs 15%) (p=0.03). Joints with joint space loss appeared to be less eroding in the MTX group than in the placebo group (8% vs 29%; p=0.2). Interleukin-6 level (p< 0.0001) and synovitis findings on MRI (p=0.02) at baseline were found to be predictive factors for erosive structural evolution of non-erosive joints. Conclusion: Our study shows that MTX did not demonstrate superior efficacy over placebo on pain and function evolution at 3 and 12 months in subjects with EHOA.. However, MTX significantly reduced the progression of joint damage compared to placebo and seems to facilitate bone remodeling. The presence of systemic and local inflammations at baseline were predictors of erosive progression.


Disclosure: s. Ferrero, None; R. Wittoek, None; E. Allado, None; C. Cruzel, None; V. Breuil, None; L. Euller Ziegler, None; D. louille, None; C. Roux, None; J. Kremer, AbbVie, 2, 5, Amgen, 5, Bristol-Myers Squibb, 2, 5, Corrona, 1, Genentech, 2, 5, Gilead, 5, Lilly, 2, 5, Novartis, 2, Pfizer, 2, 5, Regeneron, 5, Sanofi, 5.

To cite this abstract in AMA style:

Ferrero s, Wittoek R, Allado E, Cruzel C, Breuil V, Euller Ziegler L, louille D, Roux C, Kremer J. Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/methotrexate-in-patients-with-hand-erosive-osteoarthritis-refractory-to-usual-treatments-a-randomized-double-blind-placebo-controlled-trial/. Accessed May 18, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-in-patients-with-hand-erosive-osteoarthritis-refractory-to-usual-treatments-a-randomized-double-blind-placebo-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.